STOCK TITAN

Aurinia Pharmaceuticals Inc - AUPH STOCK NEWS

Welcome to our dedicated news page for Aurinia Pharmaceuticals (Ticker: AUPH), a resource for investors and traders seeking the latest updates and insights on Aurinia Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aurinia Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aurinia Pharmaceuticals's position in the market.

Rhea-AI Summary
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) reported net revenue of $41.5 million for the second quarter of 2023, a 47% increase compared to the same period last year. Year-to-date net revenue increased to $75.9 million, representing a growth of approximately 52% period over period. The company raised its net product revenue guidance for fiscal year 2023 to a range of $150 - $160 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.24%
Tags
-
Rhea-AI Summary
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) will release financial and operational results for the second quarter of 2023 on August 3, 2023. The management team will host a conference call/webcast at 8:30 am ET to review the results and provide a general business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.06%
Tags
-
Rhea-AI Summary
MKT Capital comments on Aurinia Pharmaceuticals' decision to initiate a review of strategic alternatives, including a potential value-maximizing sale, following MKT Capital's successful withhold campaign at the Annual General Meeting of Shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.71%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.68%
Tags
management
-
Rhea-AI Summary
Aurinia Pharmaceuticals presents data supporting the efficacy and safety of LUPKYNIS® for the treatment of lupus nephritis at the Annual Meeting of the European Renal Association.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.62%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.79%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.9%
Tags
none
Aurinia Pharmaceuticals Inc

Nasdaq:AUPH

AUPH Rankings

AUPH Stock Data

723.09M
131.74M
7.45%
38.61%
8.47%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Canada
Victoria

About AUPH

aurinia pharmaceuticals is a biotechnology company located in 5120-75 street, edmonton, canada.